Literature DB >> 22622462

Defective renal water handling in transgenic mice over-expressing human CD39/NTPDase1.

Yue Zhang1, Kaiya L Morris, Shannon K Sparrow, Karen M Dwyer, Keiichi Enjyoji, Simon C Robson, Bellamkonda K Kishore.   

Abstract

Ectonucleoside triphosphate diphosphohydrolase-1 hydrolyzes extracellular ATP and ADP to AMP. Previously, we showed that CD39 is expressed at several sites within the kidney and thus may impact the availability of type 2 purinergic receptor (P2-R) ligands. Because P2-Rs appear to regulate urinary concentrating ability, we have evaluated renal water handling in transgenic mice (TG) globally overexpressing hCD39. Under basal conditions, TG mice exhibited significantly impaired urinary concentration and decreased protein abundance of AQP2 in the kidney compared with wild-type (WT) mice. Urinary excretion of total nitrates/nitrites was significantly higher in TG mice, but the excretion of AVP or PGE(2) was equivalent to control WT mice. There were no significant differences in electrolyte-free water clearance or fractional excretion of sodium. Under stable hydrated conditions (gelled diet feeding), the differences between the WT and TG mice were negated, but the decrease in urine osmolality persisted. When water deprived, TG mice failed to adequately concentrate urine and exhibited impaired AVP responses. However, the increases in urinary osmolalities in response to subacute dDAVP or chronic AVP treatment were similar in TG and WT mice. These observations suggest that TG mice have impaired urinary concentrating ability despite normal AVP levels. We also note impaired AVP release in response to water deprivation but that TG kidneys are responsive to exogenous dDAVP or AVP. We infer that heightened nucleotide scavenging by increased levels of CD39 altered the release of endogenous AVP in response to dehydration. We propose that ectonucleotidases and modulated purinergic signaling impact urinary concentration and indicate potential utility of targeted therapy for the treatment of water balance disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22622462      PMCID: PMC3433867          DOI: 10.1152/ajprenal.00060.2012

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  26 in total

1.  ATP increases intracellular calcium in supraoptic neurons by activation of both P2X and P2Y purinergic receptors.

Authors:  Zhilin Song; Sukumar Vijayaraghavan; Celia D Sladek
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-09-14       Impact factor: 3.619

Review 2.  P2 receptors in the regulation of renal transport mechanisms.

Authors:  Volker Vallon
Journal:  Am J Physiol Renal Physiol       Date:  2007-10-31

3.  Nitric oxide induces phosphodiesterase 4B expression in rat pulmonary artery smooth muscle cells.

Authors:  Cornelius J Busch; Heling Liu; Amanda R Graveline; Kenneth D Bloch
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-11-18       Impact factor: 5.464

Review 4.  Intrarenal purinergic signaling in the control of renal tubular transport.

Authors:  Helle A Praetorius; Jens Leipziger
Journal:  Annu Rev Physiol       Date:  2010       Impact factor: 19.318

Review 5.  Impact of ectoenzymes on p2 and p1 receptor signaling.

Authors:  Filip Kukulski; Sébastien A Lévesque; Jean Sévigny
Journal:  Adv Pharmacol       Date:  2011

Review 6.  Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity.

Authors:  Silvia Deaglio; Simon C Robson
Journal:  Adv Pharmacol       Date:  2011

7.  Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion.

Authors:  Zhanjun Jia; Aihua Zhang; Hui Zhang; Zheng Dong; Tianxin Yang
Journal:  Circ Res       Date:  2006-11-09       Impact factor: 17.367

8.  Potential involvement of P2Y2 receptor in diuresis of postobstructive uropathy in rats.

Authors:  Yue Zhang; Donald E Kohan; Raoul D Nelson; Noel G Carlson; Bellamkonda K Kishore
Journal:  Am J Physiol Renal Physiol       Date:  2009-12-09

Review 9.  Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade.

Authors:  Gennady G Yegutkin
Journal:  Biochim Biophys Acta       Date:  2008-02-12

10.  Potential role of purinergic signaling in lithium-induced nephrogenic diabetes insipidus.

Authors:  Yue Zhang; Raoul D Nelson; Noel G Carlson; Craig D Kamerath; Donald E Kohan; Bellamkonda K Kishore
Journal:  Am J Physiol Renal Physiol       Date:  2009-02-25
View more
  5 in total

1.  Impaired natriuretic response to high-NaCl diet plus aldosterone infusion in mice overexpressing human CD39, an ectonucleotidase (NTPDase1).

Authors:  Yue Zhang; Simon C Robson; Kaiya L Morris; Kristina M Heiney; Karen M Dwyer; Bellamkonda K Kishore; Carolyn M Ecelbarger
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-15

2.  Modulation of CD39 and Exogenous APT102 Correct Immune Dysfunction in Experimental Colitis and Crohn's Disease.

Authors:  René J Robles; Samiran Mukherjee; Marta Vuerich; Anyan Xie; Rasika Harshe; Peter J Cowan; Eva Csizmadia; Yan Wu; Alan C Moss; Ridong Chen; Simon C Robson; Maria Serena Longhi
Journal:  J Crohns Colitis       Date:  2020-07-09       Impact factor: 9.071

3.  Glycogen synthase kinase 3α regulates urine concentrating mechanism in mice.

Authors:  Rikke Nørregaard; Shixin Tao; Line Nilsson; James R Woodgett; Vijayakumar Kakade; Alan S L Yu; Christiana Howard; Reena Rao
Journal:  Am J Physiol Renal Physiol       Date:  2015-01-21

4.  Clopidogrel attenuates lithium-induced alterations in renal water and sodium channels/transporters in mice.

Authors:  Yue Zhang; János Peti-Peterdi; Kristina M Heiney; Anne Riquier-Brison; Noel G Carlson; Christa E Müller; Carolyn M Ecelbarger; Bellamkonda K Kishore
Journal:  Purinergic Signal       Date:  2015-09-19       Impact factor: 3.765

Review 5.  CD39-adenosinergic axis in renal pathophysiology and therapeutics.

Authors:  Bellamkonda K Kishore; Simon C Robson; Karen M Dwyer
Journal:  Purinergic Signal       Date:  2018-01-13       Impact factor: 3.765

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.